Abstract

Introduction Congenital blood coagulation factor XII (FXII) deficiency is a rare coagulation disease and an autosomal recessive trait. It is found by chance in many cases. We identified a novel mutation (Lys346Asn) in the FXII gene of a patient with FXII deficiency, designated as Factor XII Ofunato. Methods The proband was a 75-year-old Japanese woman with a prolonged activated partial thromboplastin time (52.8 s). The FXII activity and antigen were greatly reduced (activity, 5%; antigen, 4.5%). We analyzed FXII gene of this patient using a direct sequencing method and characterized mutant FXII through in vitro expression studies. Results Sequence analysis of the FXII gene revealed a G → C point mutation at nucleotide 9845, resulting in Lys346 (AAG) → Asn (AAC) replacement in the catalytic domain. Expression studies in Chinese hamster ovary cells demonstrated that mutant FXII (346 N-FXII) showed a lower level of accumulation in the cells than wild-type. Secretion of 346 N-FXII was greatly reduced in culture medium. We also investigated mRNA expression levels of wild-type and 346 N-FXII in transfected cells using quantitative RT-PCR. Both mRNA expressions were equivalent levels. Pulse–chase experiments showed that 346 N-FXII was extensively degraded intracellularly compared to wild-type. Using membrane-permeable inhibitors, we observed that degradation occurred in the pre-Golgi compartment and that proteasome apparently plays a central role in this process. Conclusions These results show that most 346 N-FXII is degraded intracellularly through endoplasmic reticulum-associated degradation as the protein quality control system, resulting in an insufficient secretion phenotype.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.